Oncoinvent ASA Statistics

Total Valuation

Oncoinvent ASA has a market cap or net worth of NOK 221.23 million. The enterprise value is 47.18 million.

Market Cap	221.23M
Enterprise Value	47.18M

Important Dates

The last earnings date was Wednesday, April 22, 2026.

Earnings Date	Apr 22, 2026
Ex-Dividend Date	n/a

Share Statistics

Oncoinvent ASA has 4.48 million shares outstanding. The number of shares has increased by 395.91% in one year.

Current Share Class	4.48M
Shares Outstanding	4.48M
Shares Change (YoY)	+395.91%
Shares Change (QoQ)	+25,157.21%
Owned by Insiders (%)	1.27%
Owned by Institutions (%)	n/a
Float	3.00M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.88
PB Ratio	1.51
P/TBV Ratio	1.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.30
EV / Sales	1.68
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.36

Financial Position

The company has a current ratio of 3.23, with a Debt / Equity ratio of 0.02.

Current Ratio	3.23
Quick Ratio	3.20
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -121.79% and return on invested capital (ROIC) is -74.50%.

Return on Equity (ROE)	-121.79%
Return on Assets (ROA)	-52.64%
Return on Invested Capital (ROIC)	-74.50%
Return on Capital Employed (ROCE)	-107.71%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	779,694
Profits Per Employee	-4.31M
Employee Count	36
Asset Turnover	0.15
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	45.93
200-Day Moving Average	n/a
Relative Strength Index (RSI)	57.93
Average Volume (20 Days)	5,716

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncoinvent ASA had revenue of NOK 28.07 million and -155.07 million in losses. Loss per share was -1.25.

Revenue	28.07M
Gross Profit	28.07M
Operating Income	-158.33M
Pretax Income	-155.07M
Net Income	-155.07M
EBITDA	-149.80M
EBIT	-158.33M
Loss Per Share	-1.25

Full Income Statement

Balance Sheet

The company has 177.60 million in cash and 3.55 million in debt, giving a net cash position of 174.05 million or 38.87 per share.

Cash & Cash Equivalents	177.60M
Total Debt	3.55M
Net Cash	174.05M
Net Cash Per Share	38.87
Equity (Book Value)	146.32M
Book Value Per Share	0.33
Working Capital	129.35M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -129.87 million and capital expenditures -119,000, giving a free cash flow of -129.99 million.

Operating Cash Flow	-129.87M
Capital Expenditures	-119,000
Depreciation & Amortization	8.54M
Net Borrowing	-2.52M
Free Cash Flow	-129.99M
FCF Per Share	-29.03

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-564.07%
Pretax Margin	-552.46%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncoinvent ASA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-395.91%
Shareholder Yield	-395.91%
Earnings Yield	-70.09%
FCF Yield	-58.76%

Stock Splits

The last stock split was on January 19, 2026. It was a reverse split with a ratio of 0.01.

Last Split Date	Jan 19, 2026
Split Type	Reverse
Split Ratio	0.01

Scores

Oncoinvent ASA has an Altman Z-Score of -0.78 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.78
Piotroski F-Score	2